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Abstract 
Consisting of trillions of non-pathogenic bacteria living in a symbiotic relationship with their 
mammalian host, the gut microbiota has emerged in the last decades as one of the key drivers for 
cardiometabolic diseases (CMD). By degrading dietary substrates, the gut microbiota produces 
several metabolites that bind human pharmacological targets, impact subsequent signalling 
networks and in fine modulate host’s metabolism. In this review, we revisit the pharmacological 
relevance of four classes of gut microbial metabolites in CMD: short-chain fatty acids, bile acids, 
methylamines and indoles. Unravelling the signalling mechanisms of the microbial-mammalian 
metabolic axis adds one more layer of complexity to the physiopathology of CMD and opens new 
avenues for the development of microbiota-based pharmacological therapies. 
 
Keywords 
Cardiovascular diseases, Type 2 diabetes, Obesity, Gut microbiome, Microbial metabolism, signalling, 
G protein-coupled receptor, nuclear receptor. 
 
Chemical compounds studied in this article 
acetate (PubChem CID: 176), butyrate PubChem CID: 264), cholic acid (PubChem CID: 221493), 
chenodeoxycholic acid (PubChem CID: 10133), deoxycholic acid (PubChem CID: 222528), indole-3-
propionate (PubChem CID: 3744), 3-indoxylsulfate (PubChem CID: 10258), propionate (PubChem 




Cardiometabolic diseases (CMD) present a complex array of interrelated risk factors affecting more 
than 1 billion people with a dramatic impact on mortality, morbidity and quality of life [1]. These 
factors (including impaired glucose tolerance, dyslipidemia, arterial hypertension, insulin resistance 
and central obesity) are epidemiologically clustered - the presence of three of five of these 
symptoms corresponding to the “metabolic syndrome” clinical diagnosis [1]. Although many 
pharmacological mechanisms have been suggested, the underlying causes of CMD and its potential 
therapeutic avenues remain to be fully explored. With the advent of high-throughput methodologies 
(metagenomics, metabolomics), the gut microbiome emerged as one of the key drivers for CMD [2]. 
The gut ecosystem, as well as its individual members, were shown to contribute to the host 
metabolism [3]*. A lower bacterial gene count (LGC) is associated to adiposity, insulin resistance and 
dyslipidemia [4]** and dietary intervention can improve both bacterial gene richness and clinical 
metabolic outcomes [5]**. Patients with type 2 diabetes (T2D) also show specific compositional and 
functional changes in their metagenomes [6]**. 
With the increasing number of clinical studies reporting associations between the composition of 
the gut microbiota and CMD outcomes, one question arises - how are these changes in microbial 
ecology translated into pharmacological messages to the mammalian host? Consisting of trillions of 
non-pathogenic bacteria living in a symbiotic relationship with their host, gut microbiota produces 
several signalling molecules (e.g.: LPS, peptidoglycans, but also metabolites) that bind host proteins 
and impact signalling networks, therefore playing a central role as chemical messengers in the 
microbial-mammalian crosstalk [7]. The identification of the pharmacological targets and signalling 
pathways of these metabolites is key to a better understanding the molecular crosstalk supporting 
the microbial-mammalian metabolic axis – and provides a suitable framework for the discovery of 
the mechanistic basis of these associations. In this context, fine mapping of the microbial signalling 




The microbiome interacts with its host through microbial metabolites 
In this review, we shall present four classes of gut microbial metabolites impacting host molecular 
mechanisms relevant to CMD: short-chain fatty acids, bile acids, methylamines and indoles.  
Short-chain fatty acids 
Fermentation of otherwise indigestible dietary fibre by gut bacteria produces mostly short-
chain fatty acids (SCFA) (e.g. formate, acetate, propionate, butyrate, isobutyrate, valerate, 
isovalerate), which can act either as substrates and/or signalling molecules [8] (Figure 1).  
Butyrate is the primary substrate and energy source used by colonocytes [9]. Once inside the 
cell, butyrate is converted to acetyl-CoA by β-oxidation and enters the tricarboxylic acid cycle (TCA 
cycle) for energy production [8] , which leads to an inhibition of autophagy [10].  
While propionate is largely metabolised in the liver, acetate is the main SCFA in plasma [11]. 
After crossing the blood brain barrier, acetate has shown to suppress appetite and induce 
hypothalamic neuronal activation, thus modifying acetyl-CoA carboxylase activation and expression 
of neuropeptides responsible for appetite suppression [12]*. SCFA also trigger the production of 
glucagon-like peptide-1 (GLP-1), an gut hormones with anorexigenic properties [13]* [14] [15]. 
SCFAs also act as ligands for G protein-coupled receptors, therefore activating subsequent 
signalling pathways: activation of FFAR2 and FFAR3 by SCFA results in the inhibition of cAMP 
production via interaction with Gαi or Gαi/q, respectively [16].  
FFAR2 activation by SCFAs seems to have a role as a sensor for excessive dietary energy, as 
its activation suppresses insulin sensitivity and fat accumulation in adipose tissue and increases 
insulin sensitivity in liver and muscle, thus regulating energy balance [17]*. Moreover, FFAR2 
activation is also able to modulate immune responses [18] Conversely, FFAR3 activation increases 
leptin secretion, a hormone that acts as a signal of satiety [19]. Butyrate and propionate promote 
intestinal gluconeogenesis - which has beneficial effects in glucose homeostasis - by complementary 
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mechanisms: the first by activating intestinal gluconeogenesis gene expression and the second 
through FFAR3-dependent gut-brain axis [20]*. 
Butyrate is a ligand for HCAR2 (also known as GPR109A), a G protein-coupled receptor with 
anti-inflammatory activity [21] [22]. The activation of HCAR2 by nicotinic acid, a known agonist for 
this receptor, reduces the production of TNF-, IL-6 and monocyte chemoattractant protein-1 in 
monocytes [21]. The identification of butyrate as a HCAR2 agonist highlights its potential as a 
modulator of chronic low-grade inflammatory status, one of the central hallmarks of CMD. 
 
Methylamines 
Methylamines are metabolites produced from choline by the gut microbiota [18]. Choline is 
degraded into trimethylamine (TMA), which is after detoxified by the hepatic flavin-containing 
monooxygenase enzyme 3 (FMO3) into trimethylamine-N-oxide (TMAO), and demethylated into 
dimethylamine (DMA) and methylamine [for review see ref. 18]. Although the bacterial origin of 
TMA was recognised more than two decades ago [18], the members of the microbiota able to 
perform this conversion and the genes involved were only recently identified [23] [24]*. The 
bacterial genes CutC and CutD regulate the degradation of choline and are responsible for the 
regulation of the bioavailability of the circulating choline [23] [24]*. However, the recent Romano et 
al. study shows that at least one bacterial species could produce TMA in absence of the CutC gene 
[24] which suggests the existence of an alternative biosynthetic pathway. Although these genes 
were unknown at the time, we had previously shown that an increase in TMA and TMAO associated 
with a decrease in circulating choline and phosphatidylcholine played a role in the development of 
NAFLD and insulin resistance in high-fat diet fed mice [25], choline being a precursor of 
phosphatidylcholine and VLDL synthesis involved in lipid export from the liver; reducing dietary 
choline alters gut microbiota and leads to the development of non-alcoholic fatty liver disease [for a 
review, see ref. 18]. 
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TMAO was also proposed as a marker of cardiovascular disease: high plasma TMAO is associated 
with cardiovascular disease in humans and in animal models. The association between TMAO and 
CVD was then further validated [26]* and confirmed in another cohort [27]. The inhibition of FMO3 
in an atherosclerosis mouse model led to a decrease of circulating TMAO and an increase of TMA 
and has a protective effect on atherosclerosis [28]*. This FMO3 deletion also reduces plasma lipids, 
ketone bodies, glucose, insulin and hepatic lipids. This study suggests that rather than considering 
TMAO as an atherosclerosis precursor, direct roles of FMO3 in the prevention/development of 
cardiovascular diseases should be investigated. Further investigations in mice confirmed that FMO3 
deletion is beneficial for atherosclerosis and that FMO3 expression is increased in obese/insulin 
resistant subjects [29]*. 
Bile acids 
The gut microbiota contributes also to the structural diversity of circulating bile acids - indeed, 
primary bile acids (cholic acid and chenodeoxycholic acid) synthesised by the liver are conjugated 
with taurine or glycine and during enterohepatic circulation primary bile acids are deconjugated, 
hydroxylated, oxidized and epimerized by gut enzymes to form secondary bile acids [30]. The 
enterohepatic circulation of these secondary bile acids generate tertiary bile acids. The bile acids and 
their precursors oxysterols are versatile molecules with i) bacteriostatic [31], ii) emulsifying and iii) 
signalling properties. Bile acids have a beneficial effect in CMD by improving insulin sensitivity, 
hyperglycemia and dyslipidemia. Bariatric surgery studies also demonstrated that microbiome 
interventions increased circulating bile acids, which appeared to be critical for body weight loss and 
glucose homeostasis [32]** [33]. 
Bile acids regulate glucose homeostasis via several pathways, i.e., activation of Farnesoid X Receptor 
(FXR or NR1H4), Gαi protein-dependent receptor and the TGR5 receptor (or GP-BAR1, or M-BAR) 
(Figure 2) [34]. Activation of FXR by bile acids downregulates fatty acid and triglyceride synthesis in 
the liver and decreases circulating triglycerides and VLDL production (Figure 2) [34]. Bile acids also 
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increase energy expenditure through cAMP-mediated synthesis of thyroid hormone [34]. In vitro 
experiments also show that deoxycholic acid is a stronger TGR5 agonist [34] and it is a greater 
antimicrobial agent compared to cholic acid [31]. However, the potential beneficial effects of 
deoxycholic acid are offset by the fact that it can cause obesity [35] and trigger hepatocellular 
carcinoma through the senescence secretome [36]*. 
Bile acids modified by the gut microbiota, such as deoxycholic acid and lithocholic acid, are also able 
to activate alternative pathways through interactions with EGFR/FAS [37] and PXR/Vitamin D 
receptor respectively [38]. For instance, a mouse study highlighted the ability of the gut to reduce 
bile acid pool size, particularly of the primary bile acid tauro-beta-muricholic acid (TβMCA) and to 
modulate Fibroblast Growth Factor 15 (FGF15, in human FGF19), which is involved in the inhibition 
of bile acid synthesis [39]*. However, key outcomes of modified bile acid pool by the gut are still 
unclear. In addition, the major bile acids differ between mice and humans, and thus the relevance of 
these findings to humans is contentious. 
Indoles 
The gut microbiome also heavily influences metabolism of aromatic amino-acids, degrading 
tryptophan into a series indoles with signalling properties. Tryptophan is an aromatic amino acid 
that can be directly converted to indole through the activity of bacterial tryptophanase (present in 
Bacteroides thethaiotamicron, Proteus vulgaris and Escherichia coli, amongst others) [40]. Indole is 
later sulphated into 3-indoxylsulphate in the liver [40]. Conversely, Clostridium sp. and Lactobacillus 
sp. are able to deaminate tryptophan, producing indole-3-pyruvate indole-3-lactate, indole-3-
acetate and 3-methylindole [41]. 
3-indoxylsulphate induces nuclear translocation of Aryl Hydrocarbon Receptor (AhR) [42]*. AhR 
agonists enter the cell by diffusion and bind to the cytosolic inactive AhR complex, comprised by 
heat shock protein 90 (hsp90), HBB X-associated protein 2 (XAP2) and protein 23 (p23) [43,44]. Upon 
binding, the bound complex is translocated into the nucleus, resulting in the recognition of 
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xenobiotic responsive elements (XRE) and transcription of genes coding for detoxification enzymes 
(CYP1A1, CYP1A2 and CYP2S1)[43]. AhR was also shown to mediate inflammatory signalling through 
non-canonical pathways, activating NF-KB and AP-1 independently of AhR nuclear translocation [45]. 
Although initially described as a xenobiotic receptor, AHR is currently considered a physiological 
modulator of energy metabolism, as its activation is associated with both obesity and type 2 
diabetes [46]. Serum levels of 3-indoxylsulphate are associated with several deleterious cardiac 
outcomes, including left ventricular cardiac fibrosis [47]* but the underlying molecular mechanism 
remains unclear. By modulating inflammation via AHR, 3-indoxylsulphate is potentially regulating a 
core feature of CMD, which might partially explain these clinical associations [48]. 
Another indolic compound, indole-3-propionate, was also shown to play a role in two important 
mechanisms in CMD – intestinal integrity and inflammation. When the intestinal barrier becomes 
compromised, the access of both dietary antigen and pathogens is facilitated, eventually leading to 
innate immune activation, increased cytokine production and insulin resistance [48]. PXR activation 
improves inflammatory tone in intestinal bowel syndrome contexts [49]. Playing a central role in 
intestinal integrity via Pregnane X Receptor (PXR) modulation, indole-3-propionate may also play a 
beneficial role in CMD [50]*. 
Through the previous examples (Figure 3), we have shown how the gut microbial signalling 
metabolome can modulate CMD development and progression. 
Microbiome interventions 
Manipulating gut microbiota emerges, therefore, as a promising therapeutic tool to reduce CMD 
prevalence but this concept has been challenged by the difficulty of identifying rational targets.  
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Promotion of beneficial bacteria growth: prebiotic supplementation 
Nutritional interventions have proved to be a practical and easy way to modify gut bacterial 
ecosystem; healthy eating having beneficial outcomes for both the microbiome and its host. The 
growth of beneficial species can be directly promoted by the supplementation with prebiotics, 
substrates used as energy sources (i.e.: fructosyl-oligosaccharides, inulin (long-chain fructosyl-
oligosaccharide), and galactosyl-oligosaccharides) promoting the growth of beneficial bacteria. This 
concept was supported by the finding that supplementation with oligo-fructants type fibres in high-
fat-diet fed mice promoted and increased Bifidobacteria and Lactobacilli leading to an improvement 
of glucose tolerance, a reduction of endotoxemia and normalisation of the low-grade inflammatory 
status [51]. Dietary supplementations with prebiotics in mouse models was also associated with 
reduced appetite, modification of lipid metabolism in rodents [52]. In particular, galacto-
oligosaccharides supplementation in healthy mice down-regulates the activity of lipogenic enzymes 
fatty acid synthase (FAS) and the microsomal triglyceride transfer proteins (MTTP), the latter being 
involved in VLDL synthesis [53].  
Modulation of GLP-1 signalling is one of the possible routes through which prebiotics participate in 
the control of obesity and associated disorders. Treatment with the prebiotic oligofructose increases 
the total number of GLP-1 expressing cells in the colon of male Wistar rats [54]. Interestingly, 
butyrate stimulates the production of GLP-1 in intestinal cells [13], highlighting that gut microbial 
modulation with prebiotics promotes the growth of butyrate-producing bacteria, thus increasing 
GLP-1 production. In general the beneficial effects of prebiotic and probiotics have been attributed 
to the increased SCFA production [51].  
Transferring beneficial bacteria: probiotic interventions and fecal microbiota 
transplantations 
A different approach is the utilisation of probiotic bacteria as dietary supplements with the aim of 
improving human health. Treatment of high-fat diet-fed mice with the probiotic VSL#3 showed to 
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increase the levels of butyrate, and to suppress body weight gain and insulin resistance in various 
mouse models [13]*. In humans, the administration of the probiotics Lactobacillus acidophilus La5 
and Bifidobacterium lactis Bb12 significantly improved glucose homeostasis and increased total 
antioxidant status [55]. Probiotic bacteria also modulate the enterohepatic circulation and bile acids 
production [52]. A potential future probiotic treatment could also involve Akkermansia muciniphila, 
a bacteria able to reverse high-fat diet induced metabolic disorders in mice [56]**. The association 
between Akkermansia muciniphila and a healthier metabolic status has been recently validated in 
human study [57]*. 
Prebiotics and probiotics have also been used concomitantly in clinical trials – the synbiotic 
approach. As an example, the administration of a synbiotic shake, containing Lactobacillus 
acidophilus, Bifidobacterium bifidum and oligofrutose significantly increased HDL cholesterol, but no 
significant decrease was observed either in total cholesterol or triglycerides [58]. 
Faecal microbiota transplantation (FMT) was suggested as a strategy to transfer an ecologically 
stable bacterial community with beneficial properties. Studies on animal models demonstrated that 
murine microbiomes could be transplanted to impact body weight and that the architecture of the 
microbiome in obese mice matches the observations in obese patients [59] [60]*. However, the 
effect of microbiome transplantations can be mitigated by environmental influences such as co-
housing for animal models [60]*.  
Vrieze et al. showed that transplanting patients with metabolic syndrome with intestinal content 
from lean donors resulted in an improvement of both insulin sensitivity and levels of butyrate-
producing intestinal microbiota (Roseburia intestinalis and Eubacterium hallii). Hence, it can be 
speculated that this untargeted approach might be considered as a potential therapeutic strategy for 
glucose impairment disorders in humans [61].  
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Knocking down undesired bacteria: antibiotherapy and phage therapy  
A more targeted approach would be to modify the gut microbiota through the specific modulation of 
bacteria known to be associated with cardiometabolic outcomes. Antibiotic therapy has been 
recently proposed as a therapeutic tool to help restore altered gut bacterial ecosystem in obese 
humans. Vancomycin, an antibiotic with anti-Gram negative activity, promoted a large reduction in 
Firmicutes, Bacterioidetes and Proteobacteria in a diet-induced obesity model [62]*. These changes 
were accompanied by a reduction in body weight gain and improved inflammatory and metabolic 
outcomes [62]*. However, antibiotic use has important clinical limitations, since it is a non-selective 
approach that may compromise gut microbial ecosystem and select resistant strains, eventually 
leading to multiple drug resistance. Vancomycin was also associated with a simplification of gut 
bacteria bio-diversity and the opportunistic overgrowth of pathogenic bacteria such as Clostridium 
difficile causing infections and diarrhoea [63], echoing other findings on bacterial gene count.  
Phage therapy is another alternative strategy to selectively eliminate undesired bacteria. 
Bacteriophages – or “phages” – are obligate intracellular viruses that replicate inside bacteria, using 
their biosynthetic machinery. In Clostridium difficile infection, phage therapy has reduced total 
bacterial number and toxin production, without any negative impact of commensal flora [64]*. With 
the potential of phages to be genetically modified and converted into precise tools to target specific 
bacteria – and therefore, specific metabolites and signalling pathways – phage therapy surges now 
as a potentially powerful tool for gut microbiota modulation. However, the cost and the challenges 
of phage manufacturing techniques have slowed down the development of phage based therapy 
[65], as well as ethical considerations regarding the use of genetically-modified organisms as a 
potential cure for disease.  
Conclusions 
Metabolomic approaches allowed the identification and monitoring of microbial metabolites as 
potential risk markers for CMD. However, the gut microbiota is a dynamic ecological community 
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deeply affected by external stimuli, and the causality of these correlations must be interpreted 
cautiously. A more complete understanding of the targets and pathways of these metabolites is 
therefore crucial, placing the study of the pharmacology of the microbial-mammalian interaction as 
one of the most relevant areas of future research in CMD. The microbial metabolites addressed 
exemplify the broad scope of the interaction between the gut microbiota and its mammalian host, 
and their potential to influence key mechanisms of CMD (e.g. glucose homeostasis, lipid 
homeostasis, inflammation, gut barrier integrity). Revisiting the pharmacology of these four classes 
of metabolites reveals the tip of the iceberg of the mammalian-microbial pharmacological 
interaction – and suggests how potentially powerful could be the plethora of metabolites that have 
been identified, but whose targets and signaling pathways remain to be fully understood. The 
modification of the gut microbiota, its metabolites and pharmacological targets arises therefore as a 
promising therapeutic avenue. As novel and powerful analytical methods provide a clearer 
understanding complexity of this interaction, specific interventions might be designed for 
personalized healthcare approaches. 
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Figure 1. Role of butyrate in colonocytes metabolism and schematic overview of receptors 
activation by short-chain fatty acids (SCFA). (A) Butyrate produced from microbial fermentation of 
dietary fibre is transported into the colonocytes where is metabolised as major source of energy via 
TCA cycle. Butyrate also promotes hyperacetylation of histone protein by acting as HDAC inhibitor. 
SCFA bind to Free-Fatty Acid Receptors, causing the dissociation of the heterotrimeric G-protein 
complex into Gαi (FFAR3) (C) or Gαi/q (FFAR2) and (B) and Gβγ subunits. Gαi inhibits adenylate 
cyclase (AC) activity and decreases intracellular cAMP levels, with a resulting reduction in protein 
kinase A (PKA) activity. The inhibition of PKA activity leads to a decreased phosphorylation of CREB, 
therefore regulating the transcription of downstream genes. Gαq pathway activates phospholipase-
Cβ (PLC-β) which catalyses the cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 
1,4,5 triphosphate (IP3) and diacylglycerol (DAG). IP3 binds to IP3 receptors (IP3R) on the membrane 
of endoplasmic reticulum (ER) and increases the cytosolic Ca2+ concentration. Ca2+ and DAG also 
synergistically activate protein kinase C (PKC). Part of illustrations were designed using Servier 
Medical Art used under CC BY 3.0.  
 
Figure 2. Bile acid signalling and regulation of cardiometabolic risk factors. Bile acid activation of 
the Farnesoid X Receptor (FXR) regulate lipid metabolism via activation of apolipoproteins A1, C II 
and C III (apo A1, apoC II and apo C III) and inhibition of Sterol Regulatory Element Binding Protein 1c 
(SREBP-1c). In addition, glucose homeostasis is regulate by various pathways including; FOX01, 
Glucocorticoid Receptor (GR) and Hepatocyte nuclear factor 4 α (HFN4α) activated through FXR, 
Glucagon-Like Peptide-1 (GLP-1) by TGR5 receptor (or GP-BAR1, or M-BAR) and Glycogen Synthase 
(GS) by Gαi protein. 
 
Figure 3. Synoptic chart of precursors, microbial-mammalian co-metabolites and respective targets 
and effects. Gut microbiota converts dietary and endogenous substrates into metabolites that act as 
chemical messengers and modulate CMD-related outcomes. AhR: Aryl hydrocarbon receptor; CA: 
Cholic acid; CDCA: Chenodeoxycholic acid; DCA: Deoxycholic acid; FFAR2: Free fatty acid receptor 2; 
FFAR3: Free fatty acid receptor 3; FXR: Farnesoid X receptor; LCA: lithocholic acid; PXR: Pregnane X 
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